Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Outcome of pancreas transplants from 1966 to 2000

Pancreas transplant patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved, according to research published in April's Annals of Surgery.

News image

fiogf49gjkf04

A team from Minneapolis, Minnesota, USA, determined outcome in diabetic pancreas transplant recipients, according to risk factors and the surgical techniques and immunosuppressive protocols that evolved during a 33-year period at a single institution.

Clinical pancreas transplantation began at the University of Minnesota in 1966, initially with a high failure rate, but outcome improved in parallel with other organ transplants.

The authors retrospectively analyzed the factors associated with the increased success rate of pancreas transplants.

The surgeons performed 1,194 pancreas transplants (111 from living donors; 191 re-transplants) between 1966 and 2000. Of these, 498 were simultaneous pancreas-kidney (SPK) and 1 was a simultaneous pancreas-liver transplant. 404 were pancreas after kidney (PAK) transplants; and 291 were pancreas transplants alone (PTA).

The analyses were divided into five eras, depending on the type of immunosuppression and surgical technique used within the time periods: Era 0 (1966 to 1973), historical; Era 1 (1978 to 1986); Era 2 (1986-1994); Era 3 (1994-1998); and Era 4 (1998-2000).

In Era 1 patients underwent solitary (PAK and PTA) transplants involving multiple duct management techniques, and received cyclosporine for immunosuppression.

In Era 2, all varieties of pancreatic transplantation were performed (SPK, PAK, and PTA) with bladder drainage for graft duct management. Cyclosporine, azathioprine, and prednisone were used for immunosuppression.

In Era 3, tacrolimus and mycophenolate mofetil replaced the standard immunosuppressive regime of the previous era.

The surgical technique of Era 4 was primarily enteric drainage for SPK transplants. Daclizumab was used for induction immunosuppression; pre-transplant immunosuppression was used in candidates awaiting PTA.

Pancreas transplant should be an option at all stages of diabetes.
Annals of Surgery

One-year patient and graft survival rates were calculated for each category and era.

The patient survival following SPK transplant was 85% in Era 2, compared to 92% in Eras 3 and 4 combined. Graft survival was 64% and 79%, respectively.

In Era 1, patient and graft survival rates, following PAK transplants, were 86% and 17%, respectively. In Era 4 these figures were 98% and 81%.

PTA transplant patient and survival rates were 77% and 31%, and 100% and 88%, for Eras 1 and 4 respectively.

SPK graft survival rates were significantly higher with bladder drainage (82%) than enteric drainage (74%) at 1 year.

Increasing recipient age had an adverse effect on outcome only in SPK recipients. Vascular disease was found to be common; those with no vascular disease had significantly higher patient and graft survival rates in the SPK and PAK categories.

Living donor segmental pancreas transplants were associated with higher technically successful graft survival rates in each era.

The researchers found that pancreatic transplants reduced diabetic secondary complications in some recipients. Quality of life was improved in all patients.

Dr David Sutherland, of the University of Minnesota, said on behalf of the group, "Patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved.

"Eventually, islet transplants will replace pancreas transplants for suitable candidates, but currently pancreas transplants can be applied, and should be an option at all stages of diabetes. Early transplants are preferable for labile diabetes, but even patients with advanced complications can benefit," he concluded.

Ann Surg 2001; 233: 463-501
09 May 2001

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us